Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MyoKardia Inc. MYOK

Healthcare Biotechnology
"MyoKardia Inc is a US-based clinical-stage biopharmaceutical company which is engaged in discovering, developing and commercializing targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. The company mainly focuses on the treatment of heritable cardiomyopathies and genetically-driven forms of heart failure that result from biomechanical defects in cardiac... see more

Recent & Breaking News (NDAQ:MYOK)

MyoKardia Announces Pricing of Public Offering of Common Stock

GlobeNewswire May 12, 2020

MyoKardia Announces Proposed Public Offering of Common Stock

GlobeNewswire May 11, 2020

MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

GlobeNewswire May 11, 2020

MyoKardia Reports First Quarter 2020 Financial Results

GlobeNewswire May 6, 2020

MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

GlobeNewswire March 30, 2020

MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

GlobeNewswire March 26, 2020

Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology's 69th Annual Scientific Session Together with World Congress of Cardiology

GlobeNewswire March 19, 2020

MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results

GlobeNewswire February 27, 2020

MyoKardia to Present at 40th Annual Cowen Health Care Conference

GlobeNewswire February 24, 2020

MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

GlobeNewswire February 20, 2020

MyoKardia to Present at 38th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2020

MyoKardia to Present at Evercore ISI 2nd Annual HealthCONx Conference

GlobeNewswire November 27, 2019

MyoKardia Announces 48-week Data from PIONEER-OLE Study of Mavacamten

GlobeNewswire November 11, 2019

MyoKardia Announces Positive Topline Data from its Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten

GlobeNewswire November 11, 2019

MyoKardia to Present at Credit Suisse 28th Annual Healthcare Conference

GlobeNewswire November 6, 2019

MyoKardia Reports Third Quarter 2019 Financial Results

GlobeNewswire November 4, 2019

MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019

GlobeNewswire November 4, 2019

MyoKardia Announces Positive MYK-491 Data; Advancing Program into Targeted Genetic Dilated Cardiomyopathy Population

GlobeNewswire October 28, 2019

MyoKardia to Present at 2019 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2019

MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients

GlobeNewswire September 10, 2019